Back to Mobile View
Subscribe to the CrunchBase Daily for the latest on Fundings, Acquisitions, and Startup Events

Exit

Acquired byCephalon
Price$525M
Date3/2011
TermsCash and Stock

General Information

Offices

Montreal, CAN
3576 Avenue du Parc
Suite 4310, QC
Montreal, H2X 2H7, CAN

People

Chief Financial Officer
Chairman and Chief Executive Officer
Chief Scientific Officer and Co-founder
Executive Vice President and Chief Medical Officer

Funding

Tags

Gemin X Pharmaceuticals

Gemin X Pharmaceuticals is dedicated to the discovery, development and commercialization of novel, targeted cancer therapeutics to improve the lives of patients.

Gemin X’s research on the Bcl-2 cell death regulation pathway has led to the discovery of GX15-070 (obatoclax), a novel small molecule that selectively reinitiates programmed cell death, or apoptosis, and may also be effective in inducing cancer cell self-digestion, or autophagy. Obatoclax has shown promising activity in both preclinical and early human clinical studies and is currently in Phase 2 clinical trials as both a single agent and combination therapy. Obatoclax has patent protection through 2025.

Recent Milestones

Videos

Screenshots

Gemin X Pharmaceuticals screenshot
Above: Gemin X Pharmaceuticals
Uploaded: 3/11/10

Sources

  1. Cephalon Announces Definitive Agreement to Acquire Gemin X (cephalon.com) [edit]
  2. Gemin X Pharmaceuticals closes $38 Mn Series C financing (siliconindia.com) [edit]
  3. SEC (sec.gov) [edit]
  4. Gemin X books $16M Series D as it pursues PhIIb cancer trial Read more: http://www.fiercebiotech.com/story/gemin-x-books-16m-series-d-it-pursues-phiib-cancer-trial/2010-04-20#ixzz0lfnwA8xR (fiercebiotech.com) [edit]
  5. Gemin X Pharmaceuticals, Inc.: Series E $8M (onbiovc.com) [edit]
Edit This Page
Last Edited 2/25/14

Revision History RSS Picture

Sharing

Share this page on Twitter or Facebook:
Or copy this code to embed a widget: customize »

External Links

CrunchBase API

Sponsors



Become a Sponsor
Terms of Service | Privacy Policy | Licensing Policy